ArticleGlobal heart2026
Adiposity in Adults and Life Expectancy with and without Cardiovascular Disease. The Doetinchem Cohort Study.
Article in Global heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While life expectancy (LE) in the Netherlands has increased over recent decades, it is not always accompanied by good health, particularly among individuals with adiposity. As adiposity is a major risk factor for cardiovascular disease (CVD), previous studies have explored its association with LE and CVD burden, but findings remain heterogeneous. Objective: To assess the association between adiposity and LE in adults, with and without CVD. Methods: We used data from the longitudinal Doetinchem Cohort Study (DCS), including 2,323 participants aged 50-70 years (49% women). Adiposity categories were determined (low, increased, high and very high) based on the combination of body mass index (BMI) and waist circumference (WC) thresholds for overweight and obesity based on the AACE/ACE definitions. CVD and mortality were assessed via linkage to hospital and death registries. A multistate life table approach estimated total and CVD-specific LE using transition rates between three health states-CVD-free to CVD, CVD-free to death, and CVD to death-incorporating prevalences and adjusted hazard ratios (HRs) for adiposity categories by sex and CVD status. Results: LE did not differ between adiposity categories at age 50 in both men and women. Men with very high adiposity had a 2.6-year lower LE free of CVD compared to men in the low adiposity category (difference: -2.6 years, 95% CI: -3.6, -1.5), and lived more years with CVD (difference: 2 years, 95% CI: 0.9, 2.9). Men in any adiposity category lived more years with CVD than women in a similar category. In women, there were no differences in CVD-specific LE between the adiposity categories. Conclusion: Men in the very high adiposity category lived more years with CVD compared to those in the low category. These findings highlight the need for targeted cardiovascular prevention in men with very high adiposity to delay CVD onset and promote a healthy lifespan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.